Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Slideshows|December 13, 2022
Sleep in America
Author(s)Psychiatric Times Editors
Survey results shed light on the effects of insomnia and obstacles to effective treatment.
Advertisement
Advertisement
Related to this article
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
5